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Breast cancer is a clinically and molecularly heterogeneous disease. The molecular 
classification represents the foundation of treatment selection for early and advanced 
breast cancer: endocrine manipulation and/or HER2 targeted agents are administered 
on the basis of oestrogen and progesteron receptors and HER2 expression. In routine 
clinical practice, the assessment of these predictive parameters (ER, PR and HER2) is 
usually carried out in the primary tumor, and these results are also used to guide 
treatment choice in metastatic disease, even if it occurred many years after the 
primary diagnosis.   
However, the appropriateness of this approach can now be questioned for some 
reasons. First of all, several reports have been published showing a lack of 
concordance in the expression of HER2 and hormonal receptors between primary 
tumors and disease recurrence, with range of discordance between 0% and 34% and 
between 18% and 54% respectively. According to the literature data, we have 
observed in a retrospective study of 75 patients an overall disagreement of 16% in the 
HER2 status (ten patients changed from negative to positive, two cases only from 
positive to negative) and of 21% in the expression of hormonal receptors (nine cases 
changed from positive to negative and seven cases from negative to positive) from 
primary tumors to disease recurrences. Noteworthy, it has recently been reported that 
also PI3KCA mutation occurs with high frequency but differently in primary and 
metastatic breast cancer (PIK3CA mutation was detected in 45% of the primary 
tumors and in 53% of paired metastases). 
The increasing use in the adjuvant setting of targeted agents might exert selective 
pressure, possibly facilitating a modification in tumor phenotype: in fact, the change 
from a positive to negative hormonal receptor or HER2 status might reflect acquired 
resistance to hormonal or anti-HER2 therapy. But the finding that receptor status can 
change to both directions not support the hypothesis that during tumor progression, 
de-differentiation always occurs leading to a more aggressive phenotype. At the same 
time the conversion from a negative to positive phenotype can offer the patient the 
opportunity to receive a treatment that possibly could ameliorate the outcome: this 
issue has obviously direct relevance for treatment decision-making. Furthermore, new 
imaging and radiological techniques (e.g., ultrasound or computed tomography–
guided biopsy) have improved our ability to easily and safely obtain tissue samples 
from metastatic sites.  
The mechanisms underlying the change in the expression of hormonal receptors and 
HER2 have yet to be completely understood. According to intratumoral heterogeneity 
theory a clone with metastatic potential could not be detected in the primary lesion 
and could form metastatic deposits with different biologic properties. Another way is 
a possible genetic drift or a clonal selection which occurs during tumor progression or 
a selective pressure of prior therapies (as mentioned above).  
Finally the technical reproducibility of the ER, PR and HER2 assay could in part 
justify the rates of discordance, because immunohistochemistry or FISH have less 
than 100% of accuracy and  reproducibility. Several studies indicate that even when 
consecutive slides from the same tumor block are stained in different laboratories or 
interpreted by different pathologists, significant levels of discordance rates are found; 
differences in fixation methods, choice of antibody and threshold levels can also have 
a profound effect on immunohistochemistry results. 
In summary, a substantial rate of discordance in pathology and molecular markers 
between primary breast cancer and asynchronous metastases is possible and can alter 
the patient management in up to 20% of them. Tissue confirmation should be 
considered standard of care in patients with clinical and/or radiological suspicion of 
metastatic recurrence and lesions amenable to biopsy with minimal invasiveness. 
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